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Metastases from breast cancer appear to have a predilection for the
skeleton. In addition to focal skeletal disease, there is evidence
that breast cancer is associated with generalized disturbances in
skeletal metabolism.
Increased resorption and accelerated turnover of bone have been
shown in biopsies taken at sites distant from skeletal metastases
(Taube et al, 1994), perhaps mediated by the systemic secretion of
parathyroid hormone-related protein (PTHrP) which is expressed
in breast cancer tissue (Orloff et al, 1989; Powell et al, 1991).
In addition to the expression of PTHrP, both chemotherapy and
a chemotherapy-induced menopause are likely to increase the risk
of osteoporosis (Rivkees and Crawford, 1988; Saarto et al, 1997).
Whereas tamoxifen may protect against bone loss in post-
menopausal women, recent evidence suggests that bone losses
may be accelerated in women with normal ovarian function
(Powles et al, 1996; Saarto et al, 1997). For these reasons, we
wished to determine whether the risk of osteoporotic fractures was
higher in women with non-metastatic breast cancer than in the
healthy population.
PATIENTS AND METHODS
We studied two populations of women with breast cancer and a
control population of women randomly drawn from the female
population. Eighty-two women had histologically proven breast
cancer and recurrent disease diagnosed according to standard
criteria (Breast Cancer Task Force, 1977; Hayward et al, 1978),
but without skeletal metastases as judged by skeletal radiographs
and scintigraphy. They comprised a cohort of women in whom the
effects of clodronate on the incidence of skeletal metastases and
associated morbidity were studied. The findings of this trial have
been published elsewhere (Kanis et al, 1996).
After initial assessment, patients were randomized to receive
clodronate by mouth, 1600 mg daily as four capsules, or an iden-
tical placebo supplied by Leiras Oy, Helsinki, Finland. Patients
were instructed to take four capsules daily in the morning 1 h
before meals and away from calcium-containing liquids. Bone
scintigraphy and skeletal radiographs (hands, pelvis, skull, lateral
lumbar and thoracic spine) were obtained at 6-monthly intervals.
The second population of women with breast cancer comprised
352 women recruited at the time of the first diagnosis to study the
effects of clodronate, 1600 mg daily by mouth, on the incidence of
skeletal metastases. None of the women had radiographic or scinti-
graphic evidence of skeletal disease. No selection was made on the
basis of histological grade or the involvement of axillary nodes.
After diagnosis, 36% of women received tamoxifen, 18%
chemotherapy and 43% both chemotherapy and tamoxifen. After
randomization to clodronate or placebo treatment, patients were
assessed at 6-monthly intervals and spinal radiographs taken
yearly. The study is continuing and remains double blind, so that
the data are presented irrespective of treatment allocation.
A control population comprised 776 women aged 45—69 years
randomly drawn from a catchment population in London (Spector
et al, 1993). At initial assessment, 193 women (25%) were current
or past users of hormone replacement treatment (HRT). The preva-
lence of vertebral fracture was similar in women exposed to HRT
(3—6%) to that in non-users (5—7%) and the groups were combined
for analysis. All women had a radiographic assessment of the
spine which was repeated 3 years after the initial assessment.
Anteroposterior and lateral radiographs of the thoracic spine
(taken during inspiration) and the lumbar spine were obtained at a
standard target to film distance of 105 cm, with the thoracic and
lumbar film centred on T7 and L3 respectively. Radiographs were
read blindly at a single centre. The anterior, posterior and central
heights of each vertebra from T4 to L5 were reported using a
semiautomated technique and vertebral fractures defined using an
algorithm previously established (McCloskey et al, 1993). In addi-
tion, the severity of vertebral fractures was graded according to the
degree of deformity. A central compression fracture was assigned
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RESULTS
The characteristics of the three populations are shown in Table 1.
There were no differences in mean age, height or weight between
the control population and women with newly diagnosed breast
cancer, but patients with recurrent breast cancer were significantly
older than controls. Both the crude and age-adjusted prevalence of
vertebral fractures was similar in women with cancer at first diag-
nosis to that in the control population, but was more than sixfold
higher in women with soft-tissue relapse (c2 = 73.2; P < 0.0001;
Table 2). In those women with vertebral fracture, there was
no difference in the average number of fractures between the
population with newly diagnosed breast cancer and the population
controls (1.2 vs 1.4 fractures per patient respectively). The mean
number of fractures in women with recurrent breast cancer was
higher than in other groups (1.8), but the difference was not statis-
tically significant.
In contrast to data on prevalence, the incidence of vertebral frac-
ture was markedly increased in women followed from diagnosis of
breast cancer compared with normal controls. Fractures occurred
in 1.5% of controls and 5.4% of breast cancer patients followed
from diagnosis, despite a shorter duration of follow-up in the latter
(2.9 vs 2.1 years respectively). Incidence was higher in those
women with breast cancer irrespective of age (Table 3), and was
even higher in women with soft-tissue relapse but without skeletal
metastases. The age-adjusted risk of vertebral fracture was higher
in women with a prevalent fracture at study entry [odds ratio (OR),
3.4; 95% confidence interval (95% CI), 1.5—7.8]. When fracture
risk was adjusted for age, duration of follow-up and prevalent
fracture, the risk was 4.7 (95% CI, 2.3—9.9; P < 0.0001) in women
newly diagnosed with breast cancer and 22.7 (95% CI, 9.1—57.1;
P<0.0001) in the women with recurrent breast cancer. In women
with vertebral fracture, the mean number of vertebral fractures was
significantly greater in women with soft-tissue metastases than in
controls (P<0.05), and the severity of fractures was significantly
greater in these women than in controls or in women with newly
diagnosed breast cancer.
Several patients developed vertebral fractures in association
with skeletal metastases. In women followed from diagnosis,
25 (7%) developed skeletal metastases, and in women with recur-
rent breast cancer 28 (34%) developed skeletal metastases.
Because vertebral fractures may have resulted from metastatic
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Table 1 Characteristics of controls and women with breast cancer at study entry
Study group
Controls Breast cancer at diagnosis Soft-tissue relapse
Mean s.d. Mean s.d. Mean s.d.
Age (years) 54.1 6.0 54.5 10.4 59.4 10.2
Height (cm) 161.8 6.2 162.5 6.3 162.2 6.0
Weight (kg) 66.7 11.6 67.8 12.0 63.2 10.0
BMI (kg m-2) 25.4 4.1 25.6 4.3 23.9 4.1
Follow-up (years) 2.9 0.3 2.1 1.2 1.8 1.4
Table 2 Prevalence (%) of vertebral fractures
Breast cancer
Breast cancer at soft-tissue
Age Controls at diagnosis relapse
(years) (%) (%) (%)
<50 2.7 4.0 40.0
50–59 5.9 7.4 17.6
60–69 6.7 4.8 30.0
70+ – 13.0 33.0
All ages 5.2 6.0 30.5
<70 5.2 5.5 25.0
Mean number 
of fractures 1.4 1.2 1.8
Table 3 Annual incidence (%) and severity (± s.e.m.) of vertebral fractures
Breast cancer
Age Breast cancer at soft-tissue
(years) Controls (%) at diagnosis (%) relapse (%)
<50 0.45 1.87 15.38
50–59 0.25 2.68 12.00
60–69 1.06 2.87 14.63
70+ – 5.26 28.57
All ages 0.53 2.72 19.21
<70 years 0.53 2.64 13.46
>50 years 0.55 2.90 16.07
Mean number of fracturesa 1.08 ± 0.29 1.45 ± 0.94 1.69 ± 1.04
Mean severity scorea 2.00 ± 1.04 2.45 ± 1.82 4.10 ± 2.51
aIn patients with fracturedisease, incidence rates were recalculated excluding patients with
skeletal metastases. The incidence of vertebral fractures remained
significantly higher than controls in women followed from diag-
nosis (2%, OR, 2.8; 95% CI, 1.3—6.2) and in women with 
soft-tissue relapse (16.5%; OR, 24.5; 95% CI, 10.7—55.9).
DISCUSSION
The principal finding in this study was the high incidence of verte-
bral fracture in women with breast cancer, but without clinical
evidence for skeletal metastases. In women at the time of first
diagnosis of breast cancer, the incidence of vertebral fracture over
the next 3 years was nearly fivefold higher than in the normal
population. The risks were more than 20-fold greater in women
with recurrent breast cancer but no evidence of skeletal metas-
tases. The adequacy of the control population is suggested by the
observation that the prevalence of vertebral fracture was similar in
women at first diagnosis to that in women drawn randomly from
the general population. A previous study from Rochester showed
comparable findings (Utz et al, 1987). The same study also
showed an increase in risk of vertebral fractures in women with
breast cancer, but these were attributed to skeletal metastases.
It is likely that the risk of vertebral fracture is underestimated
because half of the women with breast cancer were receiving
clodronate, which has been shown to decrease the risk of vertebral
fracture both in breast cancer (Paterson et al, 1993; Kanis et al,
1996) and in osteoporosis (Filipponi et al, 1996). Clodronate also
decreases bone loss in women at the time of diagnosis of breast
cancer (Powles et al, 1997; Saarto et al, 1997). If clodronate
decreased the risk of fractures by about 50%, as suggested by these
studies, then the risks we found would be underestimated by 25%.
As mentioned, the prevalence of fracture in women with breast
cancer at the time of first diagnosis was similar to that in control
women, suggesting that the increase in risk during follow-up
depended upon factors operating subsequent to diagnosis. The
prevalence and the risk was much higher in women with soft-
tissue recurrence at a later stage of the disease, which is consistent
with this view. There were small differences in the duration of
follow-up between groups, but adjustment for these made no
difference to the risks.
It is unlikely that high rates of vertebral fracture were due to
missed skeletal metastases because the majority did not develop
spinal metastases during the conduct of the study. Moreover, as
mentioned previously, there are several reasons why bone losses
should be excessive in such patients. These considerations suggest
that vertebral fractures are related to osteoporosis. The degree of
risk is sufficiently high that intervention can be cost-effectively
targeted to women at the time of diagnosis of breast cancer (Kanis
et al, 1997). It will, however, be important to determine to what
extent alterations of menopausal status and the use of concurrent
medication affect bone loss, which because of the small sample
size was not possible in the present study.
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